Study guide
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance
Key Takeaways Explain This Topic AI
Renal blood flow (RBF) is approximately 1,200 mL/min (20-25% of resting cardiac output) with autoregulation maintaining constant RBF and GFR between a mean arterial pressure (MAP) of 80 and 180 mmHg; below 80 mmHg, GFR declines linearly and ceases below 50 mmHg.
Glomerular hemodynamics depend on opposing vascular controls: Angiotensin II preferentially constricts the efferent arteriole to sustain GFR during hypoperfusion, while prostaglandins dilate the afferent arteriole (blocked by NSAIDs, inducing prerenal AKI).
Serum anion gap is calculated as [Na+] - ([Cl-] + [HCO3-]) with normal values of 8-12 mEq/L; in hypoalbuminemia, the normal expected anion gap decreases by 2.5 mEq/L for every 1 g/dL decline in serum albumin below 4.0 g/dL.
Winter's formula evaluates respiratory compensation in metabolic acidosis: Expected PaCO2 = (1.5 x [HCO3-]) + 8 +/- 2; measured PaCO2 above expected indicates a concomitant respiratory acidosis, while PaCO2 below expected indicates a concurrent respiratory alkalosis.
KDIGO AKI Stage 1 is defined by a serum creatinine rise >=0.3 mg/dL within 48 hours or 1.5-1.9x baseline, or urine output <0.5 mL/kg/h for 6-12 hours; prerenal azotemia features a BUN:Cr ratio >20:1, FENa <1%, and urine osmolality >500 mOsm/kg.
Last updated: August 2026
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance
Mastery of renal physiology, glomerular filtration hemodynamics, neurohormonal regulation, acid-base calculations, and acute kidney injury (AKI) classification is essential for the certified registered nurse anesthetist (CRNA). General and regional anesthesia profoundly influence renal blood flow (RBF) and tubular handling of electrolytes and water. Furthermore, pre-existing renal disease alters the pharmacokinetics and pharmacodynamics of induction hypnotics, muscle relaxants, and analgesics.
1. Functional Nephron Anatomy & Segmental Tubular Physiology
The kidneys receive approximately 20% to 25% of resting cardiac output (~1,200 mL/min), representing the highest tissue perfusion rate per gram of tissue in the body. The functional unit of the kidney is the nephron , comprising approximately 1 to 1.2 million units per kidney. Nephrons are divided into cortical nephrons (~85%, located in the outer cortex with short loops of Henle) and juxtamedullary nephrons (~15%, located at the corticomedullary junction with long loops of Henle extending deep into the hypertonic renal medulla, essential for generating concentrated urine via countercurrent multiplication). Glomerulus / Bowman's Space (Filtration: 125 mL/min)
- │
- ▼
- Proximal Convoluted Tubule (PCT)
- 65-70% Na+, H2O, K+, Cl- reabsorption
- 100% glucose (threshold 180-200 mg/dL) & amino acids
- 85-90% HCO3- reabsorption (carbonic anhydrase dependent)
- Iso-osmotic reabsorption (~300 mOsm/kg)
- │
- ▼
- Loop of Henle
- Descending Thin Limb: Highly permeable to H2O (aquaporin-1), impermeable to solutes (luminal fluid concentrates to ~1200 mOsm/kg at hairpin)
• Ascending Thin Limb: Impermeable to H2O, permeable to NaCl
- Thick Ascending Limb (TAL): Impermeable to H2O; active Na+/K+/2Cl- cotransporter (NKCC2; blocked by loop diuretics); generates medullary hypertonicity
- │
- ▼
- Distal Convoluted Tubule (DCT)
- Early DCT: Impermeable to H2O (cortical diluting segment); Na+/Cl- cotransporter (NCCT; blocked by thiazides); PTH-stimulated active Ca2+ reabsorption
- Hypo-osmotic luminal fluid (~100 mOsm/kg)
- │
- ▼
- Collecting Duct (Late DCT & Medullary Collecting Duct)
- Principal Cells: ENaC channels (Na+ reabsorption), ROMK (K+ secretion), regulated by Aldosterone; Aquaporin-2 water channels inserted by ADH (V2 receptor / cAMP)
- Type A Intercalated Cells: Active H+-ATPase & H+/K+-ATPase (acid secretion, HCO3- reabsorption in acidosis)
- Type B Intercalated Cells: Pendrin (Cl-/HCO3- exchanger; HCO3- secretion, H+ reabsorption in alkalosis)
- Segmental Transport Mechanisms & Diuretic Targets
Nephron Segment Major Transporters & Channels Primary Solutes Reabsorbed / Secreted Hormonal Regulation Diuretic Drug Class & Site of Action
Proximal Tubule (PCT) Na+/H+ antiporter (NHE3), Na+/Glucose cotransporters (SGLT2/SGLT1), Carbonic Anhydrase (CA IV / CA II) Reabsorbs: 65% Na+/H2O, 100% Glucose, 85-90% HCO3-, Amino acids, Phosphate, K+ Angiotensin II (stimulates NHE3), Parathyroid Hormone (inhibits Na+/PO4 cotransporter) Carbonic Anhydrase Inhibitors (Acetazolamide; blocks HCO3- reabsorption, produces alkaline diuresis)
Thick Ascending Limb (TAL) Na+/K+/2Cl- cotransporter (NKCC2), ROMK channel (K+ back-leak creates +8 mV lumen-positive transepithelial potential driving paracellular Ca2+/Mg2+ reabsorption) Reabsorbs: 25% Na+, 25% K+, 25% Cl-, Ca2+, Mg2+; Impermeable to water Prostaglandins, Calcium-sensing receptor (CaSR) Loop Diuretics (Furosemide, Bumetanide, Torsemide; inhibit NKCC2, abolish medullary hypertonicity, cause profound diuresis and Ca2+/Mg2+ wasting)
Distal Convoluted Tubule (DCT) Na+/Cl- cotransporter (NCCT), Apical TRPV5 Ca2+ channel, Basolateral Na+/Ca2+ exchanger (NCX1) Reabsorbs: 5-7% Na+, Cl-, Ca2+; Impermeable to water Parathyroid Hormone (PTH; upregulates TRPV5 to increase Ca2+ reabsorption), Aldosterone Thiazide Diuretics (Hydrochlorothiazide, Chlorthalidone; inhibit NCCT, increase distal Ca2+ reabsorption)
Cortical & Medullary Collecting Duct Principal cells: ENaC (epithelial Na+ channel), ROMK; Intercalated cells: H+-ATPase, H+/K+-ATPase, Pendrin Principal cells: Reabsorbs 2-5% Na+, secretes K+; Intercalated cells: Secretes H+ or HCO3- Aldosterone (upregulates ENaC & basolateral Na+/K+-ATPase), ADH / Vasopressin (inserts Aquaporin-2), ANP/BNP (inhibits Na+ reabsorption) Potassium-Sparing Diuretics (Spironolactone/Eplerenone: mineralocorticoid receptor antagonists; Amiloride/Triamterene: direct ENaC blockers)
- 2. Glomerular Filtration Rate & Renal Autoregulation
- Determinants of Glomerular Filtration
Glomerular Filtration Rate (GFR) averages 125 mL/min in healthy young adults (~180 L/day). Filtration is governed by Starling forces across the glomerular capillary wall: GFR = K f × [ ( P GC − P BS ) − ( Π GC − Π BS ) ] \text{GFR} = K_f \times [ (P_{\text{GC}} - P_{\text{BS}}) - (\Pi_{\text{GC}} - \Pi_{\text{BS}}) ] GFR = K f × [( P GC − P BS ) − ( Π GC − Π BS )]
K f K_f K f = Glomerular ultrafiltration coefficient (surface area × \times × hydraulic permeability).
P GC P_{\text{GC}} P GC = Glomerular capillary hydrostatic pressure (~50-60 mmHg; favors filtration; regulated by afferent and efferent arteriolar tone).
P BS P_{\text{BS}} P BS = Bowman's space hydrostatic pressure (~15 mmHg; opposes filtration; elevated in ureteral obstruction).
Π GC \Pi_{\text{GC}} Π GC = Glomerular capillary oncotic pressure (~25 mmHg at afferent end, rising to ~35 mmHg at efferent end; opposes filtration).
Π BS \Pi_{\text{BS}} Π BS = Bowman's space oncotic pressure (~0 mmHg in healthy glomeruli).
Filtration Fraction (FF): FF = GFR RPF ≈ 125 mL/min 625 mL/min ≈ 20 % \text{FF} = \frac{\text{GFR}}{\text{RPF}} \approx \frac{125\text{ mL/min}}{625\text{ mL/min}} \approx 20\% FF = RPF GFR ≈ 625 mL/min 125 mL/min ≈ 20% .
Renal Autoregulation: Mechanisms & Limits
Renal autoregulation maintains a relatively constant Renal Blood Flow (RBF) and GFR across a Mean Arterial Pressure (MAP) range of 80 to 180 mmHg (or perfusion pressures of 75-160 mmHg). Renal Perfusion Pressure (MAP 80 - 180 mmHg)
├── 1. Myogenic Response (Fast, 1-3 seconds):
- │ Elevated transmural stretch on afferent arteriolar smooth muscle
- │ → Opens stretch-activated non-selective cation channels
- │ → Membrane depolarization & voltage-gated Ca2+ entry (L-type)
- │ → Immediate afferent arteriolar constriction (prevents hyperfiltration)
- │
└── 2. Tubuloglomerular Feedback (TGF; 10-30 seconds):
- Elevated GFR / RBF → Increased NaCl delivery to Macula Densa (TAL)
- → Increased NKCC2 transport of Na+/K+/2Cl- into macula densa cells
- → Basolateral ATP and Adenosine release
- → Binds Adenosine A1 receptors on afferent arteriolar smooth muscle
- → Afferent arteriolar vasoconstriction & inhibition of renin release AUTOREGULATION WINDOW
- RBF / GFR │ ____________________
- (mL/min) │ / \
- │ / \
- │ / \
- │ / \
- │ / \
- └────────────┴──────────────────────────────┴──────────
- 0 80 180 MAP (mmHg)
- [Linear Drop] [Glomerular Protection] [Pressure Diuresis]
NCE Clinical Pearl — The MAP Thresholds:
MAP 80–180 mmHg: Autoregulation active; GFR and RBF are held constant.
MAP < 80 mmHg: Autoregulation is exhausted; RBF and GFR decline linearly with further reductions in perfusion pressure.
MAP < 50 mmHg: Glomerular capillary hydrostatic pressure ( P GC P_{\text{GC}} P GC ) drops below opposing oncotic and Bowman's pressures; glomerular ultrafiltration ceases entirely , resulting in acute anuria.
Afferent vs. Efferent Arteriolar Control & Pharmacologic Traps
Glomerular capillary pressure ( P GC P_{\text{GC}} P GC ) and GFR are precisely tuned by modulating pre-glomerular (afferent) versus post-glomerular (efferent) arteriolar resistance:
Vascular Bed Primary Mediators Effect on Resistance Effect on Glomerular Pressure ( P GC P_{\text{GC}} P GC ) Effect on GFR Effect on RBF Anesthetic & Pharmacologic Implications
Afferent Arteriole Constriction: Endothelin, Norepinephrine, Thromboxane A2, High-dose Dopamine, TGF (Adenosine via A1) ↑ R A \uparrow R_A ↑ R A ↓ P GC \downarrow P_{\text{GC}} ↓ P GC ↓ \downarrow ↓ GFR ↓ \downarrow ↓ RBF Severe sympathetic surge / alpha-1 agonists decrease GFR.
Afferent Arteriole Dilation: Prostaglandins (PGE2, PGI2), Nitric Oxide (NO), Low-dose Dopamine, ANP/BNP ↓ R A \downarrow R_A ↓ R A ↑ P GC \uparrow P_{\text{GC}} ↑ P GC ↑ \uparrow ↑ GFR ↑ \uparrow ↑ RBF NSAIDs (Ketorolac, Ibuprofen): Inhibit COX-1/2, blocking PGE2 synthesis → \rightarrow → unchecked afferent vasoconstriction → \rightarrow → acute precipitous drop in GFR (prerenal AKI).
Efferent Arteriole Constriction: Angiotensin II (AT1 receptors, preferential low-dose effect) ↑ R E \uparrow R_E ↑ R E ↑ P GC \uparrow P_{\text{GC}} ↑ P GC ↑ \uparrow ↑ GFR (or preserved) ↓ \downarrow ↓ RBF Sustains GFR during low-flow/hypovolemic states by raising post-capillary resistance.
Efferent Arteriole Dilation: ACE inhibitors (Lisinopril, Enalaprilat), ARBs (Losartan), AT1 receptor blockers ↓ R E \downarrow R_E ↓ R E ↓ P GC \downarrow P_{\text{GC}} ↓ P GC ↓ \downarrow ↓ GFR ↑ \uparrow ↑ RBF ACEi / ARB Trap: Abolishes Angiotensin II efferent constriction → \rightarrow → efferent vasodilation → \rightarrow → profound loss of P GC P_{\text{GC}} P GC and acute drop in GFR during intraoperative hypotension.
3. Neurohormonal Control: RAAS Cascade, Aldosterone & ADH THE RAAS CASCADE
- Renal Hypoperfusion (MAP <80 mmHg) │ Decreased NaCl to Macula Densa │ Beta-1 Adrenergic Surge
- ────────────────────────────────────┼──────────────────────────────────┼─────────────────────────
- ▼
- Juxtaglomerular (JG) Granular Cells
- │
- ▼ Secretes
- RENIN (Enzyme)
- │
- Angiotensinogen (Liver) ────┴────► ANGIOTENSIN I (Decapeptide)
- │
- Pulmonary Endothelium (ACE) ──┴──► ANGIOTENSIN II (Octapeptide)
- │
- ┌───────────────────────┬────────────────────────┬───────┴────────────────────────┐
- ▼ ▼ ▼ ▼
- Potent Systemic Preferential Efferent Zona Glomerulosa (Adrenal) Hypothalamus / Pituitary
- Vasoconstriction (AT1) Arteriolar Constriction • Secretes ALDOSTERONE • Stimulates ADH release
- (Increases SVR & MAP) (Preserves GFR) • Na+ reabsorption / K+ excretion • Stimulates Thirst drive
- ADH (Vasopressin) vs. Aldosterone: Key Distinctions
Feature Aldosterone Antidiuretic Hormone (ADH / Arginine Vasopressin)
Synthesis & Secretion Site Adrenal Cortex (Zona Glomerulosa); steroid hormone Synthesized in Supraoptic & Paraventricular nuclei of Hypothalamus; stored and released from Posterior Pituitary
Primary Stimuli Angiotensin II , Hyperkalemia (direct adrenal sensing), ACTH, Hyponatremia Increased Plasma Osmolality (1-2% rise sensed by hypothalamic osmoreceptors); Hypovolemia / Hypotension (5-10% drop sensed by carotid/aortic baroreceptors)
Receptor & Intracellular Pathway Nuclear Mineralocorticoid Receptor (MR) → \rightarrow → gene transcription of ENaC, ROMK, and Na+/K+-ATPase V2 Receptors on basolateral membrane of principal cells → \rightarrow → G s → G_s \rightarrow G s → Adenylate Cyclase → \rightarrow → cAMP → \rightarrow → PKA → \rightarrow → Aquaporin-2 vesicle exocytosis; V1a Receptors on vascular smooth muscle → \rightarrow → G q → G_q \rightarrow G q → IP3/DAG/Ca2+ → \rightarrow → vasoconstriction
Renal Handling Effect Reabsorbs Na + \text{Na}^+ Na + and H 2 O \text{H}_2\text{O} H 2 O iso-osmotically; secretes K + \text{K}^+ K + and H + \text{H}^+ H + Reabsorbs free, solute-free water exclusively via Aquaporin-2 channels in collecting duct
Urine & Plasma Osmolality Impact Increases effective circulating volume; minimal direct effect on plasma tonicity Concentrates urine (up to 1,200 mOsm/kg), dilutes plasma (lowers plasma sodium and osmolality)
Pathologic Derangements Conn's Syndrome (primary hyperaldosteronism: HTN, hypokalemia, metabolic alkalosis); Addison's Disease (hypoaldosteronism: hypotension, hyperkalemia, metabolic acidosis) SIADH (euvolemic hyponatremia, high urine osmolality >100 mOsm/kg, urine Na+ >40 mEq/L); Diabetes Insipidus (hypernatremia, polyuria, low urine osmolality <300 mOsm/kg)
- 4. Acid-Base Physiology & Clinical Calculations
- Henderson-Hasselbalch Formulation
The fundamental equation describing the bicarbonate buffer system: pH = p K a + log ( [ HCO 3 − ] 0.0307 × PaCO 2 ) = 6.10 + log ( 24 0.0307 × 40 ) = 6.10 + log ( 19.54 ) = 6.10 + 1.29 = 7.39 \text{pH} = \text{p}K_a + \log \left( \frac{[\text{HCO}_3^-]}{0.0307 \times \text{PaCO}_2} \right) = 6.10 + \log \left( \frac{24}{0.0307 \times 40} \right) = 6.10 + \log(19.54) = 6.10 + 1.29 = 7.39 pH = p K a + lo g ( 0.0307 × PaCO 2 [ HCO 3 − ] ) = 6.10 + lo g ( 0.0307 × 40 24 ) = 6.10 + lo g ( 19.54 ) = 6.10 + 1.29 = 7.39
The ratio of [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] to ( 0.03 × PaCO 2 ) (0.03 \times \text{PaCO}_2) ( 0.03 × PaCO 2 ) is normally 20:1 . Any process altering this ratio shifts blood pH away from 7.40.
Primary Acid-Base Disturbances & Expected Compensation Formulas
Primary Disturbance Primary Defect Secondary Compensatory Response Formula for Expected Compensation
Metabolic Acidosis ↓ [ HCO 3 − ] \downarrow [\text{HCO}_3^-] ↓ [ HCO 3 − ] Hyperventilation ( ↓ PaCO 2 \downarrow \text{PaCO}_2 ↓ PaCO 2 ) Winter's Formula: Expected PaCO 2 = ( 1.5 × [ HCO 3 − ] ) + 8 ± 2 \text{Expected PaCO}_2 = (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2 Expected PaCO 2 = ( 1.5 × [ HCO 3 − ]) + 8 ± 2
Metabolic Alkalosis ↑ [ HCO 3 − ] \uparrow [\text{HCO}_3^-] ↑ [ HCO 3 − ] Hypoventilation ( ↑ PaCO 2 \uparrow \text{PaCO}_2 ↑ PaCO 2 ) Expected PaCO 2 = ( 0.7 × [ HCO 3 − ] ) + 20 ± 5 \text{Expected PaCO}_2 = (0.7 \times [\text{HCO}_3^-]) + 20 \pm 5 Expected PaCO 2 = ( 0.7 × [ HCO 3 − ]) + 20 ± 5 (or PaCO 2 \text{PaCO}_2 PaCO 2 rises 0.7 mmHg per 1 mEq/L rise in HCO 3 − \text{HCO}_3^- HCO 3 − )
Acute Respiratory Acidosis ↑ PaCO 2 \uparrow \text{PaCO}_2 ↑ PaCO 2 Cellular buffering (slight ↑ [ HCO 3 − ] \uparrow [\text{HCO}_3^-] ↑ [ HCO 3 − ] ) For every 10 mmHg ↑ PaCO 2 10\text{ mmHg} \uparrow \text{PaCO}_2 10 mmHg ↑ PaCO 2 : [ HCO 3 − ] ↑ 1 mEq/L [\text{HCO}_3^-] \uparrow 1\text{ mEq/L} [ HCO 3 − ] ↑ 1 mEq/L ; pH ↓ 0.08 \text{pH} \downarrow 0.08 pH ↓ 0.08
Chronic Respiratory Acidosis ↑ PaCO 2 \uparrow \text{PaCO}_2 ↑ PaCO 2 Renal HCO 3 − \text{HCO}_3^- HCO 3 − retention (3-5 days) For every 10 mmHg ↑ PaCO 2 10\text{ mmHg} \uparrow \text{PaCO}_2 10 mmHg ↑ PaCO 2 : [ HCO 3 − ] ↑ 3.5 to 4.0 mEq/L [\text{HCO}_3^-] \uparrow 3.5\text{ to }4.0\text{ mEq/L} [ HCO 3 − ] ↑ 3.5 to 4.0 mEq/L ; pH ↓ 0.03 \text{pH} \downarrow 0.03 pH ↓ 0.03
Acute Respiratory Alkalosis ↓ PaCO 2 \downarrow \text{PaCO}_2 ↓ PaCO 2 Cellular buffering (slight ↓ [ HCO 3 − ] \downarrow [\text{HCO}_3^-] ↓ [ HCO 3 − ] ) For every 10 mmHg ↓ PaCO 2 10\text{ mmHg} \downarrow \text{PaCO}_2 10 mmHg ↓ PaCO 2 : [ HCO 3 − ] ↓ 2 mEq/L [\text{HCO}_3^-] \downarrow 2\text{ mEq/L} [ HCO 3 − ] ↓ 2 mEq/L ; pH ↑ 0.08 \text{pH} \uparrow 0.08 pH ↑ 0.08
Chronic Respiratory Alkalosis ↓ PaCO 2 \downarrow \text{PaCO}_2 ↓ PaCO 2 Renal HCO 3 − \text{HCO}_3^- HCO 3 − excretion (3-5 days) For every 10 mmHg ↓ PaCO 2 10\text{ mmHg} \downarrow \text{PaCO}_2 10 mmHg ↓ PaCO 2 : [ HCO 3 − ] ↓ 4.0 to 5.0 mEq/L [\text{HCO}_3^-] \downarrow 4.0\text{ to }5.0\text{ mEq/L} [ HCO 3 − ] ↓ 4.0 to 5.0 mEq/L ; pH ↑ 0.03 \text{pH} \uparrow 0.03 pH ↑ 0.03
- Anion Gap & Delta Calculations Serum Anion Gap (AG) = [Na+] - ([Cl-] + [HCO3-])
- Normal Range: 8 to 12 mEq/L (mean ~10 mEq/L)
Correction for Hypoalbuminemia: Serum albumin is the major unmeasured anion (~2.5 mEq/L per 1 g/dL albumin). For every 1.0 g/dL drop in serum albumin below 4.0 g/dL , the normal expected baseline Anion Gap decreases by 2.5 mEq/L : Corrected Anion Gap = Observed AG + 2.5 × ( 4.0 − [ Serum Albumin in g/dL ] ) \text{Corrected Anion Gap} = \text{Observed AG} + 2.5 \times (4.0 - [\text{Serum Albumin in g/dL}]) Corrected Anion Gap = Observed AG + 2.5 × ( 4.0 − [ Serum Albumin in g/dL ])
Differential Diagnosis of Metabolic Acidosis:
High Anion Gap Metabolic Acidosis (HAGMA - "GOLD MARK"): Glycols (ethylene/propylene), Oxoproline (chronic acetaminophen), L-Lactate (sepsis, shock, hypoperfusion), D-Lactate (short bowel syndrome), Methanol, Aspirin (salicylates), Renal failure (uremia, sulfate/phosphate retention), Ketoacidosis (diabetic, alcoholic, starvation).
Normal Anion Gap / Hyperchloremic Metabolic Acidosis (NAGMA - "USEDCARP"): Ureterosigmoidostomy, Saline (0.9% NaCl resuscitation), Enteric loss (diarrhea), Drugs (Acetazolamide), Carbonic anhydrase inhibitors, Addison's disease, Renal Tubular Acidosis (Types 1, 2, 4), Pancreatic fistula.
Delta-Delta ( Δ − Δ \Delta-\Delta Δ − Δ ) Ratio: Evaluates for mixed acid-base disorders in the presence of a HAGMA: Delta Ratio = Δ AG Δ HCO 3 − = Observed AG − 10 24 − [ Measured HCO 3 − ] \text{Delta Ratio} = \frac{\Delta \text{AG}}{\Delta \text{HCO}_3^-} = \frac{\text{Observed AG} - 10}{24 - [\text{Measured } \text{HCO}_3^-]} Delta Ratio = Δ HCO 3 − Δ AG = 24 − [ Measured HCO 3 − ] Observed AG − 10
Delta Ratio = 1.0 to 2.0 \text{Delta Ratio} = 1.0\text{ to }2.0 Delta Ratio = 1.0 to 2.0 : Pure High Anion Gap Metabolic Acidosis.
Delta Ratio < 1.0 \text{Delta Ratio} < 1.0 Delta Ratio < 1.0 (or < 0.8 <0.8 < 0.8 ): Mixed HAGMA and Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (e.g., DKA treated with massive 0.9% normal saline, or lactic acidosis plus severe diarrhea).
Delta Ratio > 2.0 \text{Delta Ratio} > 2.0 Delta Ratio > 2.0 : Mixed HAGMA and Metabolic Alkalosis (e.g., DKA or lactic acidosis with concomitant nasogastric suctioning or vomiting) or pre-existing compensated chronic respiratory acidosis.
5. Acute Kidney Injury: RIFLE & KDIGO Criteria
Acute Kidney Injury (AKI) is an abrupt decline in renal function occurring over hours to days, resulting in nitrogenous waste retention (azotemia) and dysregulation of extracellular volume and electrolytes.
KDIGO Staging System for AKI
KDIGO Stage Serum Creatinine (SCr) Criteria Urine Output (UO) Criteria
Stage 1 ↑ \uparrow ↑ SCr ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL within 48 hours, OR ↑ \uparrow ↑ SCr 1.5 to 1.9 × 1.5\text{ to }1.9\times 1.5 to 1.9 × baseline within 7 days < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for 6 to 12 hours
Stage 2 ↑ \uparrow ↑ SCr 2.0 to 2.9 × 2.0\text{ to }2.9\times 2.0 to 2.9 × baseline within 7 days < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for ≥ 12 hours \ge 12\text{ hours} ≥ 12 hours
Stage 3 ↑ \uparrow ↑ SCr 3.0 × 3.0\times 3.0 × baseline within 7 days, OR ↑ \uparrow ↑ SCr ≥ 4.0 mg/dL \ge 4.0\text{ mg/dL} ≥ 4.0 mg/dL , OR initiation of Renal Replacement Therapy (RRT), OR in patients < 18 <18 < 18 years: ↓ \downarrow ↓ eGFR < 35 mL/min / 1.73 m 2 < 35\text{ mL/min}/1.73\text{m}^2 < 35 mL/min /1.73 m 2 < 0.3 mL/kg/h < 0.3\text{ mL/kg/h} < 0.3 mL/kg/h for ≥ 24 hours \ge 24\text{ hours} ≥ 24 hours , OR Anuria for ≥ 12 hours \ge 12\text{ hours} ≥ 12 hours
Prerenal Azotemia vs. Intrinsic Acute Tubular Necrosis (ATN)
Diagnostic Parameter Prerenal Azotemia (Hypoperfusion) Intrinsic AKI (Acute Tubular Necrosis) Physiologic Rationale
BUN / Serum Creatinine Ratio > 20 : 1 > 20:1 > 20 : 1 < 15 : 1 < 15:1 < 15 : 1 Urea is passively reabsorbed alongside enhanced proximal Na + \text{Na}^+ Na + and H 2 O \text{H}_2\text{O} H 2 O reabsorption in hypoperfusion; creatinine is not.
Fractional Excretion of Na + \text{Na}^+ Na + ( FENa \text{FENa} FENa ) < 1.0 % < 1.0\% < 1.0% > 2.0 % > 2.0\% > 2.0% FENa = U Na × S Cr S Na × U Cr × 100 % \text{FENa} = \frac{U_{\text{Na}} \times S_{\text{Cr}}}{S_{\text{Na}} \times U_{\text{Cr}}} \times 100\% FENa = S Na × U Cr U Na × S Cr × 100% . Intact tubules avidly reabsorb sodium in prerenal; necrotic tubular epithelial cells lose reabsorptive capacity in ATN.
Fractional Excretion of Urea ( FEUrea \text{FEUrea} FEUrea ) < 35 % < 35\% < 35% > 50 % > 50\% > 50% Use when patient has received loop diuretics (which artificially elevate urine sodium and invalidate FENa \text{FENa} FENa ).
Urine Sodium ( U Na U_{\text{Na}} U Na ) < 20 mEq/L < 20\text{ mEq/L} < 20 mEq/L > 40 mEq/L > 40\text{ mEq/L} > 40 mEq/L Avid sodium retention in intact nephrons vs. tubular salt-wasting.
Urine Osmolality > 500 mOsm/kg > 500\text{ mOsm/kg} > 500 mOsm/kg < 350 mOsm/kg < 350\text{ mOsm/kg} < 350 mOsm/kg (Isosthenuric) Intact collecting ducts concentrate urine under maximal ADH stimulation vs. loss of medullary concentrating gradient.
Urine Specific Gravity > 1.020 > 1.020 > 1.020 ∼ 1.010 \sim 1.010 ∼ 1.010 Reflects concentrated vs. dilute/isosthenuric tubular fluid.
Urine Sediment Microscopy Normal, or transparent Hyaline Casts "Muddy brown" granular casts , renal tubular epithelial (RTE) cells Sloughed necrotic tubular epithelial cells and cellular debris forming pigmented granular cylinders.
- 6. Anesthetic Effects on Renal Hemodynamics & Pharmacology
- Impact of Anesthetic Agents & Positive Pressure Ventilation
Inhalation Anesthetics & IV Hypnotics:
Volatile agents (Sevoflurane, Desflurane, Isoflurane) and IV induction agents (Propofol) cause dose-dependent myocardial depression and systemic vasodilation → \rightarrow → decrease MAP and cardiac output → \rightarrow → indirect reduction in RBF, GFR, and urine output.
Autoregulation curve shifts rightward during deep anesthesia, narrowing the protective autoregulatory window.
Mechanical Positive Pressure Ventilation & PEEP:
Increased intrathoracic pressure → \rightarrow → decreases venous return (preload) and right ventricular stroke volume → \rightarrow → decreases cardiac output.
Stimulates arterial baroreceptors and atrial stretch receptors → \rightarrow → triggers sympathetic activation, RAAS stimulation, and non-osmotic ADH release → \rightarrow → leads to oliguria and renal vasoconstriction.
Sevoflurane, Compound A & Fluoride Nephrotoxicity:
Compound A (Fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether): Formed when Sevoflurane reacts with strong base carbon dioxide absorbents (potassium hydroxide KOH \text{KOH} KOH or sodium hydroxide NaOH \text{NaOH} NaOH ) found in dry soda lime or Baralyme. Produces proximal tubular necrosis in Wistar rats.
FDA Recommendation: Maintain fresh gas flow (FGF) ≥ 1 L/min \ge 1\text{ L/min} ≥ 1 L/min for procedures lasting up to 2 hours, and ≥ 2 L/min \ge 2\text{ L/min} ≥ 2 L/min for procedures > 2 hours >2\text{ hours} > 2 hours to prevent Compound A accumulation. Modern absorbents (Amsorb, calcium hydroxide without strong bases) eliminate Compound A formation.
Inorganic Fluoride ( F − F^- F − ): Sevoflurane undergoes ~2-5% hepatic CYP2E1 metabolism releasing fluoride ions. Unlike Methoxyflurane (which produced vasopressin-resistant polyuric renal failure at serum F − > 50 μ mol/L F^- > 50\ \mu\text{mol/L} F − > 50 μ mol/L due to extensive intra-renal metabolism), Sevoflurane does not cause nephrogenic diabetes insipidus because it is rapidly cleared via the lungs and lacks intra-renal bioactivation.
Anesthetic Drug Clearance in Renal Impairment
Anesthetic Agent Route of Elimination Active / Toxic Metabolites Clinical Recommendation in End-Stage Renal Disease (ESRD)
Succinylcholine Plasma Butyrylcholinesterase (Pseudocholinesterase) None (Succinylmonocholine has < 1 % <1\% < 1% activity) Causes predictable 0.5 mEq/L 0.5\text{ mEq/L} 0.5 mEq/L rise in serum K + \text{K}^+ K + . Safe in ESRD if baseline K + ≤ 5.5 mEq/L \text{K}^+ \le 5.5\text{ mEq/L} K + ≤ 5.5 mEq/L and no denervation injury (burns, stroke, spinal cord transection).
Cisatracurium & Atracurium Hofmann Elimination (spontaneous non-enzymatic degradation at physiologic pH and temperature) + non-specific ester hydrolysis Laudanosine (CNS stimulant, epileptogenic at massive levels; clinically insignificant) Neuromuscular blockers of choice in renal failure. Clearance is completely independent of renal and hepatic function.
Rocuronium & Vecuronium Primarily hepatic metabolism and biliary excretion; Vecuronium 20-30% renal , Rocuronium 10-20% renal 3-desacetylvecuronium (active, accumulates in renal failure) Duration of action is moderately prolonged in ESRD. Monitor train-of-four (TOF); reverse with Sugammadex or Neostigmine/Glycopyrrolate.
Sugammadex Exclusively Renal (95-98% unchanged) None Forms tight 1:1 encapsulation complex with Rocuronium. Complexes remain in circulation for prolonged periods in ESRD but do not dissociate; removed by high-flux hemodialysis.
Morphine Hepatic glucuronidation Morphine-6-Glucuronide (M6G): Potent μ \mu μ -agonist (accumulates → \rightarrow → severe respiratory depression). Morphine-3-Glucuronide (M3G): Neurotoxic (hyperalgesia, myoclonus). Avoid in renal failure / ESRD.
Hydromorphone Hepatic glucuronidation Hydromorphone-3-Glucuronide (H3G): Neurotoxic, accumulates in renal failure. Use with caution at reduced doses; titrate carefully.
Meperidine Hepatic N-demethylation Normeperidine: Potent CNS stimulant (half-life 15-30 hours; accumulates in ESRD → \rightarrow → seizures, tremors). Strictly contraindicated in renal impairment.
Fentanyl, Sufentanil, Remifentanil Fentanyl/Sufentanil: Hepatic; Remifentanil: Plasma esterases No active metabolites Opioids of choice in renal failure. No toxic metabolite accumulation.